IBD Integrated Resources Portal

Prof. Wang xiaoyan

First-class Chief Physician

The Director of the Department of Gastroenterology, The Third Xiangya Hospital of Central South University. China.

Director of National Key Clinical Department.

National Committee Member of the Digestive Disease Branch of the Chinese Medical Association

Member of the IBD study group of the Digestive Disease Branch of the Chinese Medical Association.

Director of the Hunan Provincial Key Laboratory of unresolving inflammation and tumor.

Mainly engaged in the basic and clinical research of inflammatory bowel diseases and endoscopy therapy under the guidance of ultrasonic endoscope.

Received over 6 National Natural Science Foundation projects and published nearly 40 SCI papers.

Education:

B.S., clinical medicine (1988 - 1993)   Shanxi Medical University

M.D., Ph.D., Gastroenterology (1998 - 2003)   Xiangya Medicine School of Central South university

Post-doctoral Fellow, Associate (2006 – 2009; Mentor: Dr. Guiyuan Li)   Xiangya Medicine School of Central South University

(visiting)   Yale University of the United States (2010.9-2010.10)

(visiting)   University of Texas (2011.9-2012.04)

Job Experience:

Changzhi Medical College Affiliated Hospital (1993.7-1998.9), Physician

Gastroenterology Department The Third Xiangya Hospital of Central South

University (2003.7-2010.8) Attending physician, Associate professor

Gastroenterology Department The Third Xiangya Hospital of Central South

University (2010.9-) Director of Gastroenterology, Chief Physician

Publications:

1. Wang Z, Liang Q, Qian X, Hu B, Zheng Z, Wang J, Hu Y, Bao Z, Zhao K, Zhou Y, Feng X, Yi X, Li J, Shi J, Liu Z, Hao J, Chen K, Yu Y, Sham PC, Lu W, Wang X, Song W, Li MJ. An autoimmune pleiotropic SNP modulates IRF5 alternative promoter usage through ZBTB3-mediated chromatin looping. Nat Commun. 2023 Mar 3;14(1):1208. (Corresponding author)

2.Chen J, Xu F, Ruan X, Sun J, Zhang Y, Zhang H, Zhao J, Zheng J, Larsson SC, Wang X, Li X, Yuan S. Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses.   EBioMedicine. 2023 Mar;89:104494.   (Corresponding author)

3.Yuan S, Chen J, Ruan X, Sun Y, Zhang K, Wang X, Li X, Gill D, Burgess S, Giovannucci E, Larsson SC. Smoking, alcohol consumption, and 24 gastrointestinal diseases: Mendelian randomization analysis. Elife. 2023 Feb 2;12:e84051.   (Corresponding author)

4.Chen J, Ruan X, Yuan S, Deng M, Zhang H, Sun J, Yu L, Satsangi J, Larsson SC, Therdoratou E, Wang X, Li X. Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study. Aliment Pharmacol Ther. 2023 Feb;57(4):399-408. (Corresponding author)

5.Sun Y, Yuan S, Chen X, Sun J, Kalla R, Yu L, Wang L, Zhou X, Kong X, Hesketh T, Ho GT, Ding K, Dunlop M, Larsson SC, Satsangi J, Chen J, Wang X, Li X, Theodoratou E, Giovannucci EL. The Contribution of Genetic Risk and Lifestyle Factors in the Development of Adult-Onset Inflammatory Bowel Disease: A Prospective Cohort Study. Am J Gastroenterol. 2023 Mar 1;118(3):511-522.

6.Shen Z, Luo W, Tan B, Nie K, Deng M, Wu S, Xiao M, Wu X, Meng X, Tong T, Zhang C, Ma K, Liao Y, Xu J, Wang X. Roseburia intestinalis stimulates TLR5-dependent intestinal immunity against Crohn's disease. EBioMedicine. 2022 Nov;85:104285.

7.Chen H, Fu T, Dan L, Chen X,Sun Y, Chen J, Wang X, Hesketh T. Meat consumption and all-cause mortality in5763 patients with inflammatory bowel disease : A retrospective cohort study.EClinicalMedicine. 2022 Apr 21;47:101406.   (Corresponding author)

8. Chen J, Dan L, Tu X, Sun Y, Deng M, Chen X, Hesketh T, Li R, Wang X, Li X. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study. Hepatol Int. 2022 Oct 4. doi: 10.1007/s12072-022-10424-6 (Corresponding author)

9. Chen J, Wellens J, Kalla R, Fu T, Deng M, Zhang H, Yuan S, Wang X, Theodoratou E, Li X, Satsangi J. Intake of ultra-processed foods is associated with an increased risk of Crohn's disease: a cross-sectional and prospective analysis of 187,154 participants   in the UK Biobank. J Crohns Colitis. 2022 Oct 28:jjac167. doi: 10.1093/ecco-jcc/jjac167(Corresponding author)

10.Yuan S, Sun Y, Tan X, Geng J, Sun J, Chen X, Yu L, Wang J, Zhou X, Hesketh T, Larsson SC, Chen J, Wang X, Li X, Liu Z. Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study. Aliment Pharmacol Ther. 2022 Nov 9. doi: 10.1111/apt.17285 (Corresponding author)

11.    Fu T, Chen H, Chen X, Sun Y,Xie Y, Deng M, Hesketh T, Wang X, Chen J. Sugar-sweetened beverages,artificially sweetened   beverages and natural   juices   and risk of inflammatory bowel disease: a cohort study of 121,490 participants. Aliment Pharmacol Ther.2022 Jul 18. (Corresponding author)

12.   Wu S, Yuan W, Luo W, Nie K, WuX, Meng X, Shen Z, Wang X. miR-126 downregulates CXCL12 expression inintestinal epithelial   cells to suppress the   recruitment and function ofmacrophages and tumorigenesis in a murine model of colitis-associatedcolorectal cancer.   Mol Oncol. 2022 Apr 1.   (Corresponding   author)

13. Nie K, Zhang C, Deng M, Luo W,Ma K, Xu J, Wu X, Yang Y, Wang X. A Series of Genes for Predicting Responses toAnti-Tumor Necrosis Factor α Therapy in   Crohn's Disease. Front Pharmacol. 2022Apr 20;13:870796. (Corresponding author)

14.   Dan L, Chen X, Xie Y, Sun Y,Hesketh T, Wang X, Chen J. Non-linear Association between Serum25-Hydroxyvitamin D and All-cause Mortality in   Adults with   Inflammatory BowelDisease in a Prospective Cohort Study. J Nutr. 2022 Jul 11:nxac148.(Corresponding author)

15. Nie K, Yi J, Yang Y, Deng M,Yang Y, Wang T, Chen X, Zhang Z, Wang X. A Broad m6A Modification Landscape inInflammatory Bowel Disease. Front Cell Dev Biol. 2022 Jan 19;9:782636.(Corresponding author)

16. Li J, Liu J, Xu Y, Wu R, ChenX, Song X, Zeh H, Kang R, Klionsky DJ, Wang X, Tang D. Tumor heterogeneity inautophagy-dependent ferroptosis. Autophagy.   2021 Nov; 17(11):3361-3374.(Corresponding author)

17. Sun Y, Geng J, Chen X, Chen H,Wang X, Chen J, Li X, Hesketh T. Association Between Inflammatory Bowel Diseaseand Dementia: A Longitudinal Cohort Study. Inflamm Bowel Dis. 2021 Nov29:izab300. (Corresponding author)

18. Nie K, Ma K, Luo W, Shen Z,Yang Z, Xiao M, Tong T, Yang Y, Wang X. Roseburia intestinalis: A BeneficialGut Organism From the Discoveries in Genus and Species. Front Cell Infect Microbiol. 2021 Nov 22;11:757718. (Corresponding author)

19. Wu X, Pan S, Luo W, Shen Z,Meng X, Xiao M, Tan B, Nie K, Tong T, Wang X. Roseburia intestinalis‑derived flagellin ameliorates colitis by targeting miR‑223‑3p‑mediated activationof NLRP3 inflammasome and pyroptosis. Mol Med Rep. 2020 Oct;22(4):2695-2704.(Corresponding author)

20.   Li Tian, Yuanyuan Yang, DinghuaXiao, Rui Wang, Xiayu Li, Shourong Shen, Xiaoyan Wang*.Resection of gallbladderpolyps following endoscopic ultrasound-guided cholecystoduodenostomy using alumen-apposing metal stent. Endoscopy. 2018 Oct;50(10):E307-E308.(Corresponding author)

21.    Mengwei Xiao, Zhaohua Shen, Weiwei Luo, BeiTan,Xiangrui Meng, Xing Wu, Shuai Wu, Kai Nie, Ting Tong, Junbo Hong, XiaoleiWang* and Xiaoyan Wang*. A new colitis therapy strategy via the targetcolonization of magnetic nanoparticle internalized Roseburia intestinalis.Biomater. Sci.2019 Sep 24;7(10):4174-4185. (Corresponding author)

22.   Tian L, Tang AL, Zhang L, LiuXW, Li JB, Wang F, Shen SR, Wang XY*.Evaluation of 22G fineneedle aspiration(FNA) versus fine-needle biopsy (FNB) for endoscopicultrasound-guided samplingof pancreatic lesions: a prospective comparison study. Surg Endosc. 2018 Nov;32(11):4706.(Corresponding author)

23.   Shen Z, Zhu C, Quan Y, Yang J,Yuan W, Yang Z, Wu S, Luo W, Tan B, Wang X*. Insights into Roseburiaintestinalis which alleviates experimental colitis pathology by inducing anti-inflammatoryresponses, J Gastroenterol Hepatol.2018 Oct;33(10):1751-1760. (Corresponding author)

Major member

                 Deng Minzi(Ph. D)                                 Li Jingbo (MD, Ph. D)                                             Nie Kai (MD, Ph. D)

Facuty Researcher of   3rd Xiangya Hospital                            Physician and researcher of 3rd Xiangya Hospital           Physician and researcher of 3rd Xiangya Hospital

Research Assisstant experience in Stanford University      The winner of the "Youqing" fund project in Hunan.                          KASID Young Researcher Award

Brown University ，Ohio State University.                          A total of 15 SCI papers, 6 first author/corresponding                  KASID Distinguished Researcher Award

Several   first author/corresponding author papers         author papers( Autophagy, Cancer Communications, etc.).                AOCC   Distinguished Poster Award

( J Biol Chem, APT, etc.).                                                                                                                                                                ESI Highly cited and Hot Paper

                                                                                                                                                                                                  12 SCI papers (Database, Front. Cell. Infect.Microbiol, etc.).   

Other Important Members:   Dr Yang Zhenyu, Dr Shen Zhaohua, Dr Yang Yuanyuan, Dr Liu Weilin, Dr Yi Caihong, other Ph.D, MD and Master Degree candidates and so on.

Cooperation

Daolin Tang (Southwest ResearchInstitute)

Jin-MingYang (Pennsylvania State University)

Zhenming Xu（Universityof Texas Health Science Center）

Address: The Third Xiangya Hospital of Central South University

Department of Gastroenterology

Changsha, Hunan Province, China

Email: wxy20011@163.com